Study Yields Clues Into Different Leukemia Forms And Possible Therapeutic Targets
Research led by scientists at Cincinnati Children's Hospital Medical Center has revealed new clues into what causes different types of a particularly aggressive group of blood cancers known as mixed lineage leukemias (MLL) and how the disease might be treated, according to a study in Cancer Cell.
MicroRNA Controls Expression Of Oncogenes
A new study demonstrates that microRNAs can modulate the expression of well known tumor-specific oncogenic translocation proteins and may play a significant role in some human cancers. The research, published by Cell Press in the June issue of the journal Cancer Cell, is likely to lead to new strategies for treating some specific lymphomas and leukemias.
Pharmacyclics Novel Btk Inhibitor Shows Efficacy In Preclinical Models Of Rheumatoid Arthritis And Lymphoma
Pharmacyclics, Inc. (Nasdaq: PCYC) announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal model for rheumatoid arthritis (RA).
Math Could Help Cure Leukemia
When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer.In a recent study that combined math and medicine, researchers have shown that patients with chronic myelogenous leukemia (CML) may be cured of the disease with an optimally timed cancer vaccine, where the timing is determined based on their own immune response.
Results Of A Phase 3 Study Show TORISEL Significantly Improved Progression-free Survival For Patients With Relapsed refractory Mantle Cell Lymphoma
Data presented from a phase 3 clinical trial at the 44th Annual Meeting of the American Society of Clinical Oncology show that patients with relapsed and/or refractory (failed front line therapy and unresponsive to most recent treatment) mantle cell lymphoma (MCL) treated with TORISEL (temsirolim.
Galiximab In Combination With Rituximab In Patients With Previously Untreated Follicular Lymphoma
The Cancer and Leukemia Group B (CALGB) has announced data from a phase II clinical trial showing that 70 percent of patients with previously untreated follicular lymphoma responded to treatment with galiximab, an investigational anti-CD80 monoclonal antibody, when given in combination with rituximab.
Individualized Therapies For Non-Hodgkin's Lymphoma
Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT) - the first radioimmunotherapy treatment approved for use by the U.
Ability To Track Stem Cells In Tumors Could Advance Cancer Treatments
Using noninvasive molecular imaging technology, a method has been developed to track the location and activity of mesenchymal stem cells (MSCs) in the tumors of living organisms, according to researchers at SNM's 55th Annual Meeting. This ability could lead to major advances in the use of stem cell therapies to treat cancer.
England Footballer Geoff Thomas Demands Government Funding To Beat Leukeamia
Former England footballer, Geoff Thomas is pressing the Government for urgently needed cash to develop and deliver new leukaemia treatments. Thomas, a leukaemia survivor himself, is leading a presentation to the All Party Cancer Group of MPs at Westminster, at the invitation of MP's Julie Kirkbride and the committee Chairman Dr Ian Gibson on Monday June 9th.
Micromet's BiTE Antibody Blinatumomab MT103 MEDI-538 Demonstrates Durable Responses In Patients With Relapsed Non-Hodgkin's Lymphoma
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented an update of an ongoing phase 1 clinical trial for its BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland.